268 related articles for article (PubMed ID: 22125490)
1. Role of Pirh2 in mediating the regulation of p53 and c-Myc.
Hakem A; Bohgaki M; Lemmers B; Tai E; Salmena L; Matysiak-Zablocki E; Jung YS; Karaskova J; Kaustov L; Duan S; Madore J; Boutros P; Sheng Y; Chesi M; Bergsagel PL; Perez-Ordonez B; Mes-Masson AM; Penn L; Squire J; Chen X; Jurisica I; Arrowsmith C; Sanchez O; Benchimol S; Hakem R
PLoS Genet; 2011 Nov; 7(11):e1002360. PubMed ID: 22125490
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase.
Yan W; Jung YS; Zhang Y; Chen X
PLoS One; 2014; 9(8):e103497. PubMed ID: 25116336
[TBL] [Abstract][Full Text] [Related]
3. The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation.
Jung YS; Qian Y; Chen X
J Biol Chem; 2011 Oct; 286(41):35388-35395. PubMed ID: 21852228
[TBL] [Abstract][Full Text] [Related]
4. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
Duan W; Gao L; Wu X; Zhang Y; Otterson GA; Villalona-Calero MA
Exp Cell Res; 2006 Oct; 312(17):3370-8. PubMed ID: 16934800
[TBL] [Abstract][Full Text] [Related]
5. The E3 ligase PIRH2 polyubiquitylates CHK2 and regulates its turnover.
Bohgaki M; Hakem A; Halaby MJ; Bohgaki T; Li Q; Bissey PA; Shloush J; Kislinger T; Sanchez O; Sheng Y; Hakem R
Cell Death Differ; 2013 Jun; 20(6):812-22. PubMed ID: 23449389
[TBL] [Abstract][Full Text] [Related]
6. Pirh2, a ubiquitin E3 ligase, inhibits p73 transcriptional activity by promoting its ubiquitination.
Wu H; Zeinab RA; Flores ER; Leng RP
Mol Cancer Res; 2011 Dec; 9(12):1780-90. PubMed ID: 21994467
[TBL] [Abstract][Full Text] [Related]
7. Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.
Shloush J; Vlassov JE; Engson I; Duan S; Saridakis V; Dhe-Paganon S; Raught B; Sheng Y; Arrowsmith CH
J Biol Chem; 2011 Feb; 286(6):4796-808. PubMed ID: 21084285
[TBL] [Abstract][Full Text] [Related]
8. Pirh2: an E3 ligase with central roles in the regulation of cell cycle, DNA damage response, and differentiation.
Halaby MJ; Hakem R; Hakem A
Cell Cycle; 2013 Sep; 12(17):2733-7. PubMed ID: 23966173
[TBL] [Abstract][Full Text] [Related]
9. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer.
Duan W; Gao L; Druhan LJ; Zhu WG; Morrison C; Otterson GA; Villalona-Calero MA
J Natl Cancer Inst; 2004 Nov; 96(22):1718-21. PubMed ID: 15547185
[TBL] [Abstract][Full Text] [Related]
10. Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.
Jung YS; Qian Y; Chen X
FEBS Lett; 2012 May; 586(10):1397-402. PubMed ID: 22673504
[TBL] [Abstract][Full Text] [Related]
11. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation.
Leng RP; Lin Y; Ma W; Wu H; Lemmers B; Chung S; Parant JM; Lozano G; Hakem R; Benchimol S
Cell; 2003 Mar; 112(6):779-91. PubMed ID: 12654245
[TBL] [Abstract][Full Text] [Related]
12. PLAGL2 controls the stability of Pirh2, an E3 ubiquitin ligase for p53.
Zheng G; Ning J; Yang YC
Biochem Biophys Res Commun; 2007 Dec; 364(2):344-50. PubMed ID: 17950244
[TBL] [Abstract][Full Text] [Related]
13.
Qiao X; Liu Y; Prada ML; Mohan AK; Gupta A; Jaiswal A; Sharma M; Merisaari J; Haikala HM; Talvinen K; Yetukuri L; Pylvänäinen JW; Klefström J; Kronqvist P; Meinander A; Aittokallio T; Hietakangas V; Eilers M; Westermarck J
Cancer Res; 2020 Apr; 80(7):1414-1427. PubMed ID: 32029551
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis.
Sluss HK; Gannon H; Coles AH; Shen Q; Eischen CM; Jones SN
Mol Cancer Res; 2010 Feb; 8(2):216-22. PubMed ID: 20145032
[TBL] [Abstract][Full Text] [Related]
15. [TUMOR SUPPRESSOR p63 REGULATES EXPRESSION OF UBIQUITIN LIGASE Pirh2].
Daks AA; Petukhov AV; Shuvalov OY; Vasilieva EA; Melino G; Barlev NA; Fedorova OA
Tsitologiia; 2015; 57(12):876-9. PubMed ID: 26995965
[TBL] [Abstract][Full Text] [Related]
16. Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc.
Dai MS; Jin Y; Gallegos JR; Lu H
Neoplasia; 2006 Aug; 8(8):630-44. PubMed ID: 16925946
[TBL] [Abstract][Full Text] [Related]
17. Characterization of ARF-BP1/HUWE1 interactions with CTCF, MYC, ARF and p53 in MYC-driven B cell neoplasms.
Qi CF; Kim YS; Xiang S; Abdullaev Z; Torrey TA; Janz S; Kovalchuk AL; Sun J; Chen D; Cho WC; Gu W; Morse Iii HC
Int J Mol Sci; 2012; 13(5):6204-6219. PubMed ID: 22754359
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains.
Corcoran CA; Montalbano J; Sun H; He Q; Huang Y; Sheikh MS
J Biol Chem; 2009 Aug; 284(33):21955-21970. PubMed ID: 19483087
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of Pirh2 by calmodulin-dependent kinase II impairs its ability to ubiquitinate p53.
Duan S; Yao Z; Hou D; Wu Z; Zhu WG; Wu M
EMBO J; 2007 Jul; 26(13):3062-74. PubMed ID: 17568776
[TBL] [Abstract][Full Text] [Related]
20. Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1.
Hattori T; Isobe T; Abe K; Kikuchi H; Kitagawa K; Oda T; Uchida C; Kitagawa M
Cancer Res; 2007 Nov; 67(22):10789-95. PubMed ID: 18006823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
